The UKALL 2011 Trial

UKALL 2011 investigated whether small changes to the standard treatment for acute lymphoblastic leukaemia, or ALL, and lymphoblastic lymphoma, or LBL, can reduce the side effects of the treatment and reduce the chance that the disease returns.

Lymphoblastic Lymphoma or LBL is a type of cancer. It involves the lymphatic system. This is part of your immune system. It helps to fight bacteria and other infections. The treatment for LBL is already very successful. About 8 out of 10 patients are cured of the disease. There are still two problems.  First there is a risk of side effects, both during the treatment and afterwards. Second, we cannot cure all patients. We want to take the standard treatment that we currently use to treat LBL and then make a few changes.

This is to find out: 

• Whether we can reduce the side effects of the treatment 
• Whether we can reduce the chance that the disease returns. 

The complex UKALL-2011 Study was one of the TRECA trials run by the University of York. The resources were based on materials developed within a live trial at Alder Hey Children’s hospital.

As with the other TRECA Studies the media centred on an easy to use website delivering the Participant Information with a supporting Animation on the home page. We also produced a range of talking heads video content featuring the clinical researcher as well as patients and parents. These videos appeared alongside the related information in the website. The websites also included the Clinical trial animations featured below.

The particular challenge with delivering the information for the UKALL 2011 Trial was to be clear about the different treatment options. We needed multiple versions of the information tailored to the correct target age group and treatment arm.